Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has completed. Indicati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD3xCD20 bispecific antibody (bispecific antibody targeting CD3 and CD20)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED